However, despite the beneficial effects of NLRP3 inflammasome activation in anti-tumor vaccine therapy, the activation of NLRP3 inflammasomes by nanoparticles may also have adverse effects for cancer treatment due to the release of large quantities of pro-inflammatory cytokines (e.g., TGF-β). The gene discussed is NLRP3; the disease is neoplasm.